Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Byoung Chul Cho

Showing results (21-30 of 453) with videos related to

Pageof 46
Sort By:
Frontiers in Bioengineering and Biotechnology|March 6, 2023
Artificial intelligence-based non-small cell lung cancer transcriptome RNA-sequence analysis technology selection guideMin Soo Joo, Kyoung-Ho Pyo, Jong-Moon Chung, et al.
Cancer Treatment Reviews|June 13, 2021
The promise of bispecific antibodies: Clinical applications and challengesSun Min Lim, Kyoung-Ho Pyo, Ross A Soo, et al.
Journal of Thoracic Disease|January 21, 2012
The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancerPei-Jye Voon, Byoung Chul Cho, Wee-Lee Yeo, et al.
Head & Neck|December 12, 2018
Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunityHyang Joo Ryu, Eun Kyung Kim, Byoung Chul Cho, et al.
Head & Neck|March 18, 2024
Durvalumab in combination with chemoradiotherapy in patients with head and neck squamous cell carcinoma: Results from the Phase 1 CLOVER studyJulie E Bauman, Sana D Karam, Cathy O'Brien, et al.
Thoracic Cancer|January 15, 2016
Tumor MET expression profile predicts the outcome of non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitorsHyun Chang, Xianglan Zhang, Byoung Chul Cho, et al.
Clinical Lung Cancer|December 8, 2022
Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical ApplicationsByoung Chul Cho, Allison Simi, Joshua Sabari, et al.
European Journal of Cancer (Oxford, England : 1990)|October 21, 2018
A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathySeo Young Lee, Min Hwan Kim, Mi Jang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 2, 2014
Immunotherapy in the treatment of non-small cell lung cancerRaghav Sundar, Richie Soong, Byoung-Chul Cho, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 5, 2025
A Response to the Letter to the Editor: "Comparable or Indeterminate? A Critical Appraisal of Efficacy Claims in the MARIPOSA Exploratory Analysis"Se-Hoon Lee, Shun Lu, John Xie, et al.
Pageof 46

Showing results (21-30 of 453) with videos related to

Sort By:
Pageof 46
Frontiers in Bioengineering and Biotechnology|March 6, 2023
Artificial intelligence-based non-small cell lung cancer transcriptome RNA-sequence analysis technology selection guideMin Soo Joo, Kyoung-Ho Pyo, Jong-Moon Chung, et al.
Cancer Treatment Reviews|June 13, 2021
The promise of bispecific antibodies: Clinical applications and challengesSun Min Lim, Kyoung-Ho Pyo, Ross A Soo, et al.
Journal of Thoracic Disease|January 21, 2012
The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancerPei-Jye Voon, Byoung Chul Cho, Wee-Lee Yeo, et al.
Head & Neck|December 12, 2018
Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunityHyang Joo Ryu, Eun Kyung Kim, Byoung Chul Cho, et al.
Head & Neck|March 18, 2024
Durvalumab in combination with chemoradiotherapy in patients with head and neck squamous cell carcinoma: Results from the Phase 1 CLOVER studyJulie E Bauman, Sana D Karam, Cathy O'Brien, et al.
Thoracic Cancer|January 15, 2016
Tumor MET expression profile predicts the outcome of non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitorsHyun Chang, Xianglan Zhang, Byoung Chul Cho, et al.
Clinical Lung Cancer|December 8, 2022
Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical ApplicationsByoung Chul Cho, Allison Simi, Joshua Sabari, et al.
European Journal of Cancer (Oxford, England : 1990)|October 21, 2018
A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathySeo Young Lee, Min Hwan Kim, Mi Jang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 2, 2014
Immunotherapy in the treatment of non-small cell lung cancerRaghav Sundar, Richie Soong, Byoung-Chul Cho, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 5, 2025
A Response to the Letter to the Editor: "Comparable or Indeterminate? A Critical Appraisal of Efficacy Claims in the MARIPOSA Exploratory Analysis"Se-Hoon Lee, Shun Lu, John Xie, et al.
Pageof 46